Phenome-Wide Association Studies (PheWAS) are a high throughput approach to evaluate comprehensive associations between genetic variants and a wide range of phenotypic measures. One of the main challenges with PheWAS is the varying sample size ranges of cases and controls across the many phenotypes of interest, that could affect statistical power to detect associations. The motivation of this study is to investigate the parameters, including sample size, that affect estimation of statistical power in PheWAS.
Background
PheWAS approaches have been implemented in variety of different studies like the eMERGE network [1] [2] [3] [4] [5] with electronic health record information that includes international classification of disease version 9 (ICD-9) code based diagnoses, laboratory test measurements and demographic information. Other PheWAS include data from epidemiological studies [6, 7] , as well as clinical trials [8, 9] such as the AIDS clinical trial group (ACTG) which collected a range of measurements for different clinical domains like pharmacology, metabolism, virology, and immunology [8, 9] . Cohorts like these with large number of measurements for every individual have made PheWAS an effective approach to scan over hundreds and thousands of associations in a high-throughput way. PheWAS serve as a great tool to generate genetic association hypotheses for multiple phenotypes as well as provide insights in cross-phenotype associations. Unlike a GWAS where one phenotype is evaluated, PheWAS utilizes a wide range of phenotypes collected for a variety of biological interests for each dataset. Thus in PheWAS, the data collected for different measurements can vary dramatically in sample size, including specifically the numbers of cases for diagnoses can be considerably different depending on the rarity of the diagnosis. This makes the estimation of statistical power for PheWAS a challenge. For example, in electronic health record (EHR) data, one of the most commonly used data types are ICD-9 codes; these codes provide information on disease diagnosis, procedures, and medications in the form of 3-5 digit codes. The longitudinal ICD-9 data collected over many years varies drastically between patients due to multiple factors such as differences in the frequency of patient visits, differences in length of records due to varying start and end dates, and lack of medical history with outpatient data. These factors generate sparseness and missing information in the data and hence variability in number of cases, case-control ratio, as well as overall sample size in case-control study designs. These factors could potentially affect the estimations from association testing.
The goal of this study is to perform power estimations altering number of parameters encountered in PheWAS, to determine the appropriate thresholds to use for number of cases or total sample size, as well as the ratio of cases to controls for a given phenotype. It is challenging to make study design decisions regarding sample size at the outset of a PheWAS from an EHR with either case-control phenotypes (ICD-9 codes) or quantitative trait phenotypes (clinical lab variables) as the number of cases or samples will vary for each phenotype. We run into three issues with low sample size phenotypes: 1) we have low statistical power to identify or replicate any associations and 2) we may potentially have biased estimates in analyses with low sample size, and 3) we increase our multiple hypothesis testing burden by testing low powered phenotypes. In this paper, we investigate a number of different factors that could influence the statistical power in association testing with a PheWAS and these simulations can provide empirically derived evidence to guide future PheWAS study designs.
Methods:

Simulation Study
We designed a simulation approach with different combinations of genotype and phenotype parameters and then performed association testing to investigate the factors that could influence the statistical power to detect a signal.
The design process for a binary disease outcome was to simulate datasets with different number of cases, and for each count of cases we evaluated all permutations of parameters including: case to control ratio, minor allele frequency, and several disease penetrance measures. We used R to generate random population-based samples with genotypes and their disease status using different input parameters aforementioned. For example, we generated one simulated model with 10 cases and 10 controls when case to control ratio is 1:1, 0.01 minor allele frequency, 0.15 disease penetrance and an additive genotype model (0,1,2). Under each simulation model, we generated 1000 datasets for each combination and then calculated associations using logistic regression for binary traits and linear regression for quantitative traits implemented in the statistical package PLATO (http://ritchielab.psu.edu/plato). Please refer to Table 1 for all the different combinations of parameter values used for simulation.
For the continuous or quantitative trait simulations, we investigated the power estimates by varying the sample size, and for each bin we evaluated the power for different permutations of minor allele frequency and disease penetrance. Again, we generated 1000 datasets for each combination and then used linear regression to calculate associations with the quantitative traits. Please refer to Table 2 for all the different combinations of parameter values used for the quantitative trait simulations. 
Results
Binary variable simulation
We designed a simulation approach with different combinations of genotype and phenotype parameters and then performed association testing to investigate the factors that could influence power to detect a signal as explained ablove. We performed all permutations of the parameter settings shown in Table 1 .
In Figure 1 , we show trends in the estimates of power at a p-value of 0.01 for different parameters used for simulation. First, we observed an increase in power with an increase in penetrance irrespective of any change in other parameters and this is expected as highly penetrant disease are more likely to be identified even with small numbers of samples (this is due to having a high effect size). We also identified that the ratio between cases and controls does not have much impact on the power. It is actually the number of cases that largely influences the power to detect genetic associations. For example, as shown in Figure 1 , the case-control ratio has inconsiderable affect on power whereas with the increase in case number we see three times increase in power to identify an association. These simulations also show the importance of minor allele frequency threshold when calculating associations on genotype models with an additive effect. Here, we find that all of the simulation models showed increased performance with minor allele frequency greater than 5%. The model with lower frequency variants (MAF between 1% and 5%) did not reach 100% power until the case threshold was increased to 1000 samples and the model exhibited high disease penetrance. 
Quantitative trait simulation
We also performed similar simulation analysis on quantitative measurements (such as clinical lab variables) to identify a sample size threshold for multi-phenotype based studies like PheWAS. We used the same parameter matrix for simulations as was done for binary variables with the exception of the cases and case-control ratio ( Table 2) . For quantitative traits, we use different sample size numbers for the simulation ranging from 10 to 25,000, as these are based on estimates of sample sizes we observe in EHR or clinical trials datasets. In Figure 2 , we show a similar graph as in the binary variable simulation where the x-axis has different sample sizes of the data set and on y-axis is the power of association. We observed almost no power until the dataset had approximately 1000 samples for a phenotype with penetrance of 0.15 and as expected we see the increase in power with higher penetrance even at smaller sample sizes. Around the sample size of 1000, we see an increase in power with slight variation with different minor allele frequencies. Again variants with rare minor alleles did not perform well until a sample size of 1000 and penetrance of 0.3. These quantitative variable simulations suggest that a threshold of 1000 samples for models with MAF greater than 5% in PheWAS and larger sample size or different statistical approach to evaluate rare variants. 
Discussion
PheWAS provides a great genomic landscape of multiple phenotypes, but a challenge of PheWAS is the range of sample sizes and case numbers that is inherent with large EHR or clinical trials-based datasets. For example, there are 14,025 possible ICD-9 diagnosis codes and 3,824 procedure codes used by EHR systems within healthcare provider organizations.
With the introduction of ICD-10, the number of ICD-based codes has further increased to approximately 69,000. PheWAS is a high throughput approach to test for hundreds and thousands of variables, but testing 14,025 diagnosis codes for association with up to 1-million or more genetic variants can result in a very high multiple testing burden. Also, a large fraction of codes will have very low case numbers due to rarity of the disease, and thus may not be sufficiently powered for association detection. For example, Geisinger Heath System (GHS) is one of the largest health care providers in central Pennsylvania with an EHR including ~1.2 million unique patients. We looked into the GHS EHR data of around 100,000 participants consented into the MyCode® Community Health Initiative [10] to evaluate the extent of the variability in number of ICD-9 codes by case sample count. In order to account for misdiagnosis of missing medical history, it is advisable to define a patient as a case for an ICD-9 code only when they have three or more visits in their EHR where that specific code was represented in the patient record. Out of 14,025 codes, 33% are not coded at all and ~30% fewer than 10 patients with that code (case count <10). As shown in Figure 3 , even after dropping out more than 60% of the ICD-9 codes there are still 3,568 codes with 10 or more patients labeled as cases, which still adds to the multiple hypothesis burden. As we identified in our binary trait simulation, the power for identifying association shows considerable increase at a case threshold of 200 with power estimates > 50% for common variant (MAF > 0.01). In the GHS EHR data, there are 831 ICD-9 codes with at least 200 patients labelled as case (as shown in Figure 3 ). We recommend using 200 as a case threshold for a common variant PheWAS analysis as it provides enough power to identify the association and also reduces multiple hypothesis burden by excluding low confidence ICD-9 codes. In the case of PheWAS on quantitative traits, our simulation suggests that a sample size of 1000 individuals will provide enough power to identify an association.
Conclusions
PheWAS have become a common tool to explore the genotype-phenotype landscape of large biobanks linked to comprehensive phenotype/trait data collections as in EHRs, clinical trials, or epidemiological cohort studies. This high-throughput analysis approach has been met with much success in recent years (cite some PheWAS papers from the literature). However, the community has been lacking guidance for making study design decisions regarding sample size, case to control ratios, and minor allele frequency. At present, there is not a PheWAS Power Calculator available to researchers. Thus, we implemented a large-scale simulation study to provide some guidelines for understanding the statistical power of PheWAS analyses under different scenarios. We believe these simulation results provide the needed power estimates for future PheWAS analysis decisions. 
